Friday, March 29, 2024 2:03:00 AM
Good news for MTNB
"We project that the market for MAT2203 in the treatment of invasive aspergillosis in patients with limited treatment options could reach peak sales in the U.S. alone of over $400 million annually..."
"We project that the market for MAT2203 in the treatment of invasive aspergillosis in patients with limited treatment options could reach peak sales in the U.S. alone of over $400 million annually..."
Recent MTNB News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 09:01:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 09:00:36 PM
- Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards • GlobeNewswire Inc. • 04/03/2026 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2026 10:05:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2025 10:00:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/21/2025 10:15:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/10/2025 09:06:14 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/25/2025 07:52:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/18/2025 10:30:39 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2025 09:00:20 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/23/2025 09:14:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/23/2025 08:05:20 PM
